Figure 3. 1st MSA patient on nasal foralumab

Figure 3. 1st MSA patient on nasal foralumab

Marked reduction in basal ganglia uptake following nasal foralumab

Format

PNG

Source

Tiziana Life Sciences Ltd.

Téléchargements